Literature DB >> 8195247

Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis.

Y J Zhang1, B J Rutledge, B J Rollins.   

Abstract

Monocyte chemoattractant protein-1 (MCP-1) is a monocyte-specific chemoattractant and activator and is a member of the chemokine-beta family of cytokines. To identify regions of MCP-1 which are required for its biological activity, we constructed human MCP-1 mutants that were expressed in eukaryotic cells and tested for their ability to attract monocytes in vitro. Deletion of amino acids 2-8 destroyed activity, suggesting that the amino-terminal region is necessary for activity. Within the deleted region, mutation of aspartate 3 to alanine produced a protein with 9% of wild-type activity, whereas mutation of asparagine 6 to alanine produced a protein with 52.9% of wild-type activity. Mutation of amino acids within the first intercysteine loop yielded variable results. Changing tyrosine 28 to aspartate or arginine 30 to leucine each produced proteins with essentially no monocyte chemoattractant activity. The side chains of these amino acids are predicted to point into a putative receptor binding cleft, and these loss-of-function mutations are consistent with this model. Also consistent is the retention of 60% of wild-type activity after mutation of serine 27 to glutamine, since the side chain of serine 27 is predicted to point away from the binding cleft. However, mutation of arginine 24, which lies outside of this area, to phenylalanine produced a protein with only 5% of wild-type activity, suggesting more complex interactions. Truncations of the carboxyl terminus, as well as mutation of aspartate 68 to leucine, generated proteins with 10-20% of wild-type activity. (Another carboxyl-terminal insertional mutation demonstrated that O-linked carbohydrate in MCP-1 alpha may be added to a threonine in the carboxyl-terminal region.) These findings are consistent with a structural model of dimeric MCP-1 which is similar to interleukin-8, in which amino acids that point into a cleft between the two carboxyl-terminal alpha-helices of the subunits are important for receptor binding. In addition, however, amino acids at the amino terminus and others outside of the interhelical cleft are also essential for activity. The carboxyl-terminal alpha-helix is not required for signaling per se but is required for maximal specific activity. Finally, four mutant proteins partially inhibited the ability of wild-type MCP-1 to attract monocytes in vitro.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195247

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Identification of chemokines and a chemokine receptor in cichlid fish, shark, and lamprey.

Authors:  Noriyuki Kuroda; Tatiana S Uinuk-ool; Akie Sato; Irene E Samonte; Felipe Figueroa; Werner E Mayer; Jan Klein
Journal:  Immunogenetics       Date:  2003-03-05       Impact factor: 2.846

3.  Soluble overexpression and purification of bioactive human CCL2 in E. coli by maltose-binding protein.

Authors:  Thu Trang Thi Vu; Bon-Kyung Koo; Jung-A Song; Seon-Ha Chong; Cho Rong Park; Minh Tan Nguyen; Boram Jeong; Han-Bong Ryu; Jae Young Seong; Yeon Jin Jang; Robert Charles Robinson; Han Choe
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

4.  Mutant monocyte chemoattractant protein 1 protein attenuates migration of and inflammatory cytokine release by macrophages exposed to orthopedic implant wear particles.

Authors:  Zhenyu Yao; Michael Keeney; Tzu-Hua Lin; Jukka Pajarinen; Katherine Barcay; Heather Waters; Kensuke Egashira; Fan Yang; Stuart Goodman
Journal:  J Biomed Mater Res A       Date:  2013-11-20       Impact factor: 4.396

5.  A three-dimensional in vitro model to demonstrate the haptotactic effect of monocyte chemoattractant protein-1 on atherosclerosis-associated monocyte migration.

Authors:  Neda Ghousifam; Hamid Mortazavian; Rudra Bhowmick; Yolanda Vasquez; Frank D Blum; Heather Gappa-Fahlenkamp
Journal:  Int J Biol Macromol       Date:  2016-12-29       Impact factor: 6.953

6.  Local delivery of mutant CCL2 protein-reduced orthopaedic implant wear particle-induced osteolysis and inflammation in vivo.

Authors:  Xinyi Jiang; Taishi Sato; Zhenyu Yao; Michael Keeney; Jukka Pajarinen; Tzu-Hua Lin; Florence Loi; Kensuke Egashira; Stuart Goodman; Fan Yang
Journal:  J Orthop Res       Date:  2015-07-29       Impact factor: 3.494

Review 7.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

Review 8.  Chemokines: understanding their role in T-lymphocyte biology.

Authors:  S G Ward; J Westwick
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

9.  The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation.

Authors:  Themis R Kyriakides; Matt J Foster; Grant E Keeney; Annabel Tsai; Cecilia M Giachelli; Ian Clark-Lewis; Barrett J Rollins; Paul Bornstein
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4.

Authors:  S K Gupta; T Hassel; J P Singh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.